Indeed, in a preclinical study, targeting IL1RAP using a monoclonal antibody induced selective killing of AML CD34posCD38pos, and CD34posCD38neg cells both in vitro and in a xenograft model (164). Here, IL1RAP is linked to acute myeloid leukemia.